JTJuliano Timm

Juliano Timm

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Juliano Timm has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Eugene Sun

    TB Alliance, USA

    3 shared publications
  • Adam A. Witney

    Affiliation Institute of Infection and Immunity, St George’s, University of London, London, United Kingdom

    2 shared publications
  • Anna Bateson

    Affiliation Centre for Clinical Microbiology, University College London, Royal Free Campus, London, United Kingdom

    2 shared publications
  • Morounfolu Olugbosi

    TB Alliance, South Africa

    2 shared publications
  • Timothy D. McHugh

    Affiliation Centre for Clinical Microbiology, University College London, Royal Free Campus, London, United Kingdom

    2 shared publications
  • A. Gebhard

    KNCV Tuberculosis Foundation, The Hague, the Netherlands

    1 shared publication

Latest Publications

  • Open Access

    High efficacy of BPaL among patients infected with Mycobacterium tuberculosis lineage 1 in the Philippines

    by I. Flores, M.A.A. Tujan, R. Basilio, T.J.R. Dizon, D.R Lim, L.T. Reyes, R.V.A.G. Reyes, S. Rojas, A.K. Valencia, J.B. Capin, et al.

    SUMMARY: BACKGROUND: WHO recommends the bedaquiline–pretomanid–linezolid regimen with/without moxifloxacin (M) (BPaL/M) for the treatment of multidrug- or rifampicin-resistant TB. However, Mycobacterium tuberculosis (MTB) lineage 1 (L1) is less susceptible to pretomanid than other lineages, and there are limited BPaL/M efficacy data from regions where L1 is prevalent. METHODS: We performed whole genome sequencing (WGS) on baseline MTB isolates from a subgroup (34/103) of patients from the highly successful Philippine BPaL Operational Research Study to characterise their lineage and genotypic drug susceptibility testing (DST) profile. Phenotypic DST for BPaL drugs was also conducted. RESULTS: WGS analysis showed that L1 (68%) predominated, followed by L4 (26%) and L2 (6%). Out of the 22 L1 isolates tested, 20 exhibited higher pretomanid minimum inhibitory concentrations than isolates from other lineages, including one with borderline resistance. Two patients had confirmed bedaquiline resistance; no linezolid resistance was detected. All 34 patients with characterised isolates had culture converted by end of treatment. At month 12 follow-up, 30/31 patients who provided sputum remained culture negative; the single culture-positive participant harboured MTB L4. CONCLUSION: In this study, patients infected with MTB L1 responded to BPaL as well as those infected with other lineages. Baseline bedaquiline resistance was linked to the unique recurrence in the study.


  • Open Access

    PA-459 The effect on treatment outcomes of baseline resistance to pyrazinamide after 6-months of BPaMZ in the SimpliciTB clinical trial

    by Juliano Timm, Timothy McHugh, Angela Crook, Jerry Nedelman, Morounfolu Olugbosi, Stephen H Gillespie, Maria Beumont, Eugene Sun

    Background The combination of bedaquiline, pretomanid, moxifloxacin, and pyrazinamide (BPaMZ) provides the shortest duration of treatment required to sterilize mice in relapsing mouse models. SimpliciTB was an open-label study to evaluate the safety and efficacy of 4-months BPaMZ (4BPaMZ) compared to standard therapy (4HRZE/2HR) in DS-TB participants. The trial also included a cohort of DR-TB participants who received 6-months BPaMZ (6BPaMZ). The primary efficacy endpoint was time to culture negative status through 8 weeks; the key secondary endpoint was relapse-free cure at week 52. The proportions of patients with culture conversion by 8 weeks and of favorable outcome at week 52 (MITT analysis) for 4HRZE/2HR, 4BPaMZ and 6BPaMZ were 47.3%, 84.1%, 85.7% and 93.1%, 85.3%, 83.1%, respectively. The lower rates of favorable outcomes in BPaMZ arms were largely due to higher rates of hepatotoxicity-related trial discontinuations, in which PZA may have contributed. Methods Using Kaplan-Meier (KM) and Cox PH models adjusting for socio-demographic and clinical factors, we explored the effect on outcome of baseline resistance to pyrazinamide (BRZ) in the DR-TB group of participants. Results 55 of 152 (36.2%) participants in the DR-TB cohort had BRZ based on phenotypic and genotypic drug susceptibility testing. Time to negative sputum culture for patients with and without BRZ was not statistically significantly different (aHR=0.79, 95% CI (0.54,1.15) p= 0.22). Relapse-free cure was documented in 42/51 (82%) participants with and 68/79 (86%) participants without BRZ (unadjusted Chi-sq test p=0.57). Conclusion PZA resistance at baseline did not impact outcomes at week 8 or week 52 in DR-TB patients treated with BPaMZ. A regimen of pretomanid, moxifloxacin with a potent diarylquinoline could present an efficacious and better tolerated therapeutic alternative for DS- and DR-TB patients and should also be explored as a therapeutic option for DS-TB.

  • Top Cited Papers
    Open Access

    Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid

    by Juliano Timm, Anna Bateson, Priya Solanki, Ana Paleckyte, Adam A. Witney, Sylvia A. D. Rofael, Stella Fabiane, Morounfolu Olugbosi, Timothy D. McHugh, Eugene Sun

    Bedaquiline (B), pretomanid (Pa) and linezolid (L) are key components of new regimens for treating rifampicin-resistant tuberculosis (TB). However, there is limited information on the global prevalence of resistance to these drugs and the impact of resistance on treatment outcomes. Mycobacterium tuberculosis (MTB) phenotypic drug susceptibility and whole-genome sequence (WGS) data, as well as patient profiles from 4 pretomanid-containing trials–STAND, Nix-TB, ZeNix and SimpliciTB–were used to investigate the rates of baseline resistance (BR) and acquired resistance (AR) to BPaL drugs, as well as their genetic basis, risk factors and impact on treatment outcomes. Data from >1,000 TB patients enrolled from 2015 to 2020 in 12 countries was assessed. We identified 2 (0.3%) participants with linezolid BR. Pretomanid BR was also rare, with similar rates across TB drug resistance types (0–2.1%). In contrast, bedaquiline BR was more prevalent among participants with highly resistant TB or longer prior treatment histories than those with newly diagnosed disease (5.2–6.3% vs. 0–0.3%). Bedaquiline BR was a risk factor for bacteriological failure or relapse in Nix-TB/ZeNix; 3/12 (25%, 95% CI 5–57%) participants with vs. 6/185 (3.2%, 1.2–6.9%) without bedaquiline BR. Across trials, we observed no linezolid AR, and only 3 cases of bedaquiline AR, including 2 participants with poor adherence. Overall, pretomanid AR was also rare, except in ZeNix patients with bedaquiline BR. WGS analyses revealed novel mutations in canonical resistant genes and, in 7 MTB isolates, the genetic determinants could not be identified. The overall low rates of BR to linezolid and pretomanid, and to a lesser extent to bedaquiline, observed in the pretomanid trials are in support of the worldwide implementation of BPaL-based regimens. Similarly, the overall low AR rates observed suggest BPaL drugs are better protected in the regimens trialed here than in other regimens combining bedaquiline with more, but less effective drugs.


  • Open Access

    Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid

    by Anna Bateson, Julio Ortiz Canseco, Timothy D. McHugh, Adam A. Witney, Silke Feuerriegel, Matthias Merker, Thomas A. Kohl, Christian Utpatel, Stefan Niemann, Sönke Andres, et al.

    To develop a robust phenotypic antimicrobial susceptibility testing (AST) method with a correctly set breakpoint for pretomanid (Pa), the most recently approved anti-tuberculosis drug. The Becton Dickinson Mycobacterial Growth Indicator Tube™ (MGIT) system was used at six laboratories to determine the MICs of a phylogenetically diverse collection of 356 Mycobacterium tuberculosis complex (MTBC) strains to establish the epidemiological cut-off value for pretomanid. MICs were correlated with WGS data to study the genetic basis of differences in the susceptibility to pretomanid. We observed ancient differences in the susceptibility to pretomanid among various members of MTBC. Most notably, lineage 1 of M. tuberculosis, which is estimated to account for 28% of tuberculosis cases globally, was less susceptible than lineages 2, 3, 4 and 7 of M. tuberculosis, resulting in a 99th percentile of 2 mg/L for lineage 1 compared with 0.5 mg/L for the remaining M. tuberculosis lineages. Moreover, we observed that higher MICs (≥8 mg/L), which probably confer resistance, had recently evolved independently in six different M. tuberculosis strains. Unlike the aforementioned ancient differences in susceptibility, these recent differences were likely caused by mutations in the known pretomanid resistance genes. In light of these findings, the provisional critical concentration of 1 mg/L for MGIT set by EMA must be re-evaluated. More broadly, these findings underline the importance of considering the global diversity of MTBC during clinical development of drugs and when defining breakpoints for AST.